Peter W. Kenny
Curriculum Vitae, September 2013

Personal/contact details

Born: 09-04-1959, Port of Spain, Trinidad
Citizenship: Dual national of UK and Trinidad and Tobago
Email: pwk.pub.2008@gmail.com
Telephone: +44 7765043186
Skype: peter.w.kenny
LinkedIn: http://www.linkedin.com/pub/0/ab9/870
Blog: Fragment-based drug discovery and molecular design
Twitter: @pwk2013

Profile

Physical-organic, computational and medicinal chemist with molecular design focus. 20+ years of experience in lead generation, screening library design and lead optimisation. Specific interests include fragment-based drug discovery, hydrogen bonding, lipophilicity and automated editing of chemical structures (e.g. for tautomers and matched molecular pairs).

Employment history

2012 (May) - 2013 (June): Universidade de São Paulo (IQSC); Visiting Researcher

2011 (Dec) - 2012 (Feb): CSIRO (Parkville); Visiting Scientist

2011 (May - July): OpenEye Scientific Software; Visiting Scientist

2010 (Jan - April): CSIRO (Parkville); Visiting Scientist

2009 (Aug - Sept): Universidade de São Paulo (IQSC); Visiting Researcher

1988 - 2009: AstraZeneca (formerly Zeneca; ICI Pharmaceuticals); Principal Scientist at retirement.

1985 - 1987: University of Minnesota; Post-doctoral Research Associate

1983 - 1985: University of the West Indies St Augustine; Assistant Lecturer and Demonstrator

Education

1979-1982: Oxford University, DPhil Physical-Organic Chemistry. Thesis Title: NMR Studies of Reaction Mechanisms

1976-1979: Reading University, BSc Chemistry with Subsidiary Mathematics, First Class Honours.

Non-professional interests

I enjoy travel and working in different countries and am interested in history. When opportunities present themselves, I also scuba dive and ski.

Selected publications (2004-2013)

Kenny PW, Montanari CA, Prokopcyck IM, Sala FA, Sartori GR (2013) **Automated molecule editing in molecular design.** JCAMD 27:655-664 DOI

Kenny PW, Montanari CA, Prokopcyck IM (2013) **ClogP$_{alk}$: A method for prediction of alkane/water partition coefficient.** JCAMD 27:389-402 DOI

Kenny PW, Montanari CA (2013) **Inflation of correlation in the pursuit of drug-likeness.** JCAMD 27:1-13 DOI

Dossetter AG, Beeley H, Bowyer J, Cook CR, Crawford JJ, Finlayson JE, Heron NM, Heyes C, Highton AJ, Hudson JA, Jestel A, Kenny PW, Krapp S, Martin S, MacFaul PA, McGuire TM, Gutierrez PM, Morley AD, Morris JJ, Page KM, Ribeiro LR, Sawney H, Steinbacher S, Smith C, Vickers M (2012) **(1R,2R)-N-(1-Cyanocyclopropyl)-2-(6-methoxy-1,3,4,5-tetrahydropyrido[4,3-b]indole-2carbonyl)cyclohexanecarboxamide (AZD4996): A Potent and Highly Selective Cathepsin K Inhibitor for the Treatment of Osteoarthritis.** JMC 55:6363-6374 DOI

Bethel PA, Gerhardt S, Jones EV, Kenny PW, Karoutchi GI, Morley AD, Oldham K, Rankine N, Augustin M, Krapp S, Simader H, Steinbacher S (2009) **Design of selective Cathepsin inhibitors.** BMCL 19:4622-4625 DOI

Kenny PW (2009) **Hydrogen bonding, electrostatic potential and molecular design.** JCIM 49:1234-1244 DOI

Blomberg, N, Cosgrove DA, Kenny PW, Kolmodin, K. (2009) **Design of compound libraries for fragment screening.** JCAMD 23:513-525 DOI

Birch AM, Kenny PW**, S**impson I, Whittamore PRO (2009) **Matched molecular pair analysis of activity and properties of glycogen phosphorylase inhibitors.** BCML 19:850-853 DOI

Toulmin A, Wood JM, Kenny PW (2008) **Toward Prediction of Alkane/Water Partition Coefficients.** JMC 51:3720-3730 DOI

Albert, JS, Blomberg N, Breeze AL, Brown AJH, Burrows JN, Edwards PD, Folmer, RHA, Geschwindner S, Griffen EJ, Kenny PW, Nowak T, Olsson L-L, Sanganee H, Shapiro AB (2007) **An integrated approach to fragment-based lead generation: philosophy, strategy and case studies from AstraZeneca's drug discovery programmes.** Curr Top Med Chem 7:1600-1629 link

Birch AM, Kenny PW, Oikonomakos NG, Otterbein L, Schofield P, Whittamore PRO, Whalley DP (2007) **Development of potent, orally active 1-substituted-3,4-dihydro-2-quinolone glycogen phosphorylase inhibitors**. BMCL 17:394-399 DOI

Bower JF, Kenny PW, Poyser JP (2007) **Piperazine derivatives, processes for preparing them, pharmaceutical compositions containing them, and their use as antagonists of CC chemokines (CCR2b and CCR5) for the treatment of inflammatory diseases.** PCT Int. Appl. 2007, 110pp. WO 2007071952 link

Leach AG, Jones HD, Cosgrove DA, Kenny PW, Ruston L, MacFaul P, Wood JM, Colclough N, Law, B (2006) **Matched Molecular Pairs as a Guide in the Optimization of Pharmaceutical Properties; a Study of Aqueous Solubility, Plasma Protein Binding and Oral Exposure**, JMC 49:6672-6682 DOI

Kenny PW, Sadowski J (2005) **Structure modification in chemical databases**, Methods and Principles in Medicinal Chemistry 2005, 23 (Chemoinformatics in Drug Discovery, ed Oprea T) 271-285 DOI

Black E, Breed J, Breeze AL, Embrey K, Garcia R, Gero TW, Godfrey L, Kenny PW**,** Morley AD, Minshull CA, Pannifer AD,. Read J, Rees A, Russell DJ, Toader, D, Tucker J (2005) **Structure-based design of protein tyrosine phosphatase-1B inhibitors**, BMCL 15:2503-2507 DOI

Lyne PD, Kenny PW, Cosgrove DA, Deng C, Zabludoff S, Wendoloski JJ, Ashwell, S (2004) **Identification of Compounds with Nanomolar Binding Affinity for Checkpoint Kinase-1 Using Knowledge-Based Virtual Screening**, JMC 47:1962-1968 DOI

Kenny PW, Morley AD, Russell DJ, Toader D (2004) **Preparation of 1,2,5-thiadiazolidin-3-one 1,1-dioxide derivatives as inhibitors of protein tyrosine phosphatase 1B.** PCT Int. Appl. 2004, 48pp. WO 2004050646 link

Birch AM, Kenny PW, Morley AD, Russell DJ. Toader, D (2004) **Preparation of 5-(substituted phenyl)thiadiazolidin-3-ones as inhibitors of protein tyrosine phosphatase 1B.** PCT Int. Appl. 2004, 89pp . WO 2004041799 link